S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Michigan Ear Institute Joins Align ENT & Allergy in Strategic Merger

The Michigan Ear Institute has finalized a strategic partnership with Align ENT & Allergy, a move aimed at scaling specialized otological and neurotological care across Michigan and Ohio. The transaction, which closed March 25, 2026, marks a significant consolidation for the Farmington Hills-based practice under the Zenyth Partners-backed platform.

Michigan Ear Institute Joins Align ENT & Allergy in Strategic Merger
Photo: Bio & News

Physician Growth Partners served as the exclusive financial advisor for the deal, steering the institute through a complex negotiation process. The Michigan Ear Institute operates four clinics and maintains a reputation for managing intricate conditions ranging from pediatric hearing loss to skull base surgery. Dr. Robert Hong, a partner at the institute, credited the advisory firm's navigation of the transaction as instrumental in securing the final outcome.

Align ENT & Allergy, founded in 2022, operates as a physician-led management services organization. By integrating the institute into its network, Align continues its strategy of acquiring independent specialty practices while maintaining local clinical autonomy. For Physician Growth Partners, the deal represents another addition to their portfolio of over 80 closed transactions within the healthcare services sector, further solidifying their role in facilitating private equity-backed medical practice transitions.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!